DRMA שווי כולל של נכסי החברה Dermata Therapeutics Inc

Dermata Therapeutics (DRMA) is implementing automated systems for molecule analysis and the processing of trial data sets. Since the business is at a pre-commercial stage and focused on testing, there is no revenue or free cash flow. This chart shows that the total assets amount to 5.98. Dermata Therapeutics (DRMA) aims to capture the rosacea and acne drug niche by utilizing innovative drug delivery methods.

In an oversaturated dermatological products market, the expansion of Dermata Therapeutics (DRMA) via microneedle innovations requires significant resources; therefore, a reverse valuation of total asset value calculated through ROA without time lags allows for tracking the actual scale of control over property and capital, helping investors distinguish organic growth of the production base from the hidden accumulation of risky liabilities.